Mainstay Medical Mainstay Medical Announces Board Change

 
TIDMIRSH 
 
 

Mainstay Medical International plc ("Mainstay" or the "Company", Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on commercializing ReActiv8®, an implantable restorative neurostimulation system designed to treat an underlying cause of disabling Chronic Low Back Pain, today announces that Dr Manus Rogan has decided to step down as a Non-Executive Director of the Company with immediate effect in order to concentrate on other commitments.

Dr Rogan has been a Board member of the Company since its IPO on Euronext Paris and Euronext Dublin in 2014. In 2012, Dr Rogan (as Managing Partner of Fountain Healthcare Partners) led the $20M Series B financing into Mainstay Medical Ltd. and the relocation of the Company's head office from Minneapolis to Dublin. He also joined the board of Mainstay Medical Ltd. at that time.

Dr Oern Stuge, Chairman of the Board of Mainstay, said: "During his time as a director, Manus has seen Mainstay's technology and business mature significantly to the point where we now have the ReActiv8-B study nearing completion and our commercialization strategy in Europe gaining traction. We thank him for his significant contribution to that journey and wish him every success in the future."

Dr Rogan said: "I am proud of the progress Mainstay has made and believe the Company has a bright future. With a strong team in place and a clear roadmap for the commercialization of ReActiv8 internationally, now is a good time for me to step down to focus on earlier stage investments. I am fully supportive of Mainstay's strategy and look forward to its continued success."

- End -

About Mainstay

Mainstay is a medical device company focused on commercializing an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands, and is listed on the regulated market of Euronext Paris (MSTY.PA) and the ESM of Euronext Dublin (MSTY.IE).

About Chronic Low Back Pain

One of the recognized root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilize the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilization put a significant burden on individuals, families, communities, industry and governments.

Further information can be found at www.mainstay-medical.com

CAUTION - in the United States, ReActiv8 is limited by federal law to investigational use only.

Forward looking statements

This announcement includes statements that are, or may be deemed to be, forward looking statements. These forward looking statements can be identified by the use of forward looking terminology, including the terms "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "should", "will", or "explore" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward looking statements include all matters that are not historical facts. They appear throughout this announcement and include, but are not limited to, statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, prospects, financing strategies, expectations for product design and development, regulatory applications and approvals, reimbursement arrangements, costs of sales and market penetration and other commercial performance.

By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances. Forward looking statements are not guarantees of future performance and the actual results of the Company's operations, and the development of its main product, the markets and the industry in which the Company operates, may differ materially from those described in, or suggested by, the forward looking statements contained in this announcement. In addition, even if the Company's results of operations, financial position and growth, and the development of its main product and the markets and the industry in which the Company operates, are consistent with the forward looking statements contained in this announcement, those results or developments may not be indicative of results or developments in subsequent periods. A number of factors could cause results and developments of the Company to differ materially from those expressed or implied by the forward looking statements including, without limitation, the successful launch and commercialization of ReActiv8, the progress and success of the ReActiv8-B Clinical Study,general economic and business conditions, global medical device market conditions, industry trends, competition, changes in law or regulation, changes in taxation regimes, the availability and cost of capital, the time required to commence and complete clinical trials, the time and process required to obtain regulatory approvals, currency fluctuations, changes in its business strategy, and political and economic uncertainty. The forward-looking statements herein speak only at the date of this announcement.

PR and IR Enquiries:Consilium Strategic Communications (international strategic communications - business and trade media)Chris Gardner, Jessica Hodgson, Nicholas BrownTel: [phone] / [phone]Email: [e-mail] Consulting (for Ireland):Jonathan NeilanTel: [phone]Email: [e-mail] (for France)Julie CoulotTel: [phone]Email: [e-mail]/Kötting Consulting (for Germany)Andreas BohneTel : [phone]Email : [e-mail] KöttingTel: [phone]Email: [e-mail] Relations:LifeSci Advisors, LLCBrian RitchieTel: + 1 [phone]Email: [e-mail] Advisers:DavyFergal Meegan or Barry MurphyTel: [phone]Email: [e-mail] or [e-mail]

View source version on businesswire.com: https://www.businesswire.com/news/home/20180923005040/en/

 
This information is provided by Business Wire 
 
 

(END) Dow Jones Newswires

September 24, 2018 02:00 ET (06:00 GMT)